New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Hematology"
DOI: 10.1007/s12185-021-03112-y
Abstract: Chronic myelogenous leukemia (CML) stem cells are the cellular source of the vast majority of mature CML cells and responsible for relapse of CML disease post-tyrosine kinase inhibitor (TKI) therapy. Although mature CML cells, whose… read more here.
Keywords: cml stem; metabolism; chronic myelogenous; stem ... See more keywords
Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells
Sign Up to like & getrecommendations! Published in 2017 at "Oncogene"
DOI: 10.1038/onc.2017.85
Abstract: B-cell CLL/lymphoma 6 (BCL6) exerts oncogenic effects in several human hematopoietic malignancies including chronic myeloid leukemia (CML), where BCL6 expression was shown to be essential for CML stem cell survival and self-renewal during imatinib mesylate… read more here.
Keywords: cml stem; cml; ifn; bcl6 ... See more keywords
Metabolic Adaptation to Tyrosine Kinase Inhibition in Leukemia Stem Cells.
Sign Up to like & getrecommendations! Published in 2023 at "Blood"
DOI: 10.1182/blood.2022018196
Abstract: Tyrosine kinase inhibitors (TKI) are very effective in treating chronic myelogenous leukemia (CML), but primitive, quiescent leukemia stem cells persist as a barrier to cure. We performed a comprehensive evaluation of metabolic adaptation to TKI… read more here.
Keywords: stem; stem cells; cml stem; tki treatment ... See more keywords